Promising Agent Identified as Specific Antidote to Factor Xa Inhibition

Summary

Antidotes to Factor Xa inhibitors are under development and should enhance the safety of the new oral anticoagulant (NOAC) agents. Reversal of a NOAC is necessary in certain circumstances, such as a spontaneous or provoked hemorrhage (rate of 10% to 20% in Phase 3 trials), an emergency or invasive procedure that requires the rapid reversal of anticoagulation, or serious bleeding in a critical organ.

  • Cardiology Clinical Trials
  • Thrombotic Disorders
  • Cardiology & Cardiovascular Medicine
  • Cardiology Clinical Trials
  • Thrombotic Disorders
View Full Text